2017 PKU Intl Symposium attracted more than 300+ people onsite, coming from government, bio-pharmaceuticals, scientific research institutions, hospitals, investment circus, legal units and medical media. Over 100 insiders from Boston, San Francisco, Santiago, Princeton, Toronto, Singapore, Beijing, Tianjin, Nanjing, Suzhou, Chengdu, Wuhan, Chongqing, Guangzhou, Shenzhen, Guiyang, Hong Kong, Taipei, etc. participated the Symposium via webcast.
 
ATTENDEES：
Roche, Johnson & Johnson, Novartis, AstraZeneca, AbbVie, Bayer, Boehringer-Ingelheim, MSD, Betta Pharmaceuticals, WuXi AppTec, Qilu Pharmaceutical, Tasly, Zai Lab, BeiGene, Harbour BioMed, SPH, BGI, Adagene, Jiangsu Hengrui Medicine, HitGen, Shanghai Junshi Biosciences, Shanghai Hutchison Pharmaceuticals, FMD, 3D Medicines, R&G PharmaStudies
Guotouchuangye, CR Group, Morningside, Lilly Asia Ventures, Mintangel Fund, FGPA
Kyoto University, Japan National Cancer Center, Hokkaido University, Singapore National Cancer Center, University of British Columbia, Tsinghua University, Shanghai Jiao Tong University School of Medicine, Fudan University, Tianjin University, Sun Yat-sen University, CAS Shanghai Institute of Materia Medica, Nanjing University, University of Science and Technology of China, China Pharmaceutical University, Soochow University, 301 Hospital, The Second Military Medical University, Army Medical University, Harbin Medical University